What Dulera Treats: Main Uses and Benefits

This medication is commonly used for the chronic, daily treatment of persistent asthma in patients who require additional symptomatic support. It is applied across therapeutic domains where patients experience conditions characterized by periods of heightened symptoms, and is considered relevant in clinical settings that involve persistent symptom patterns.

Dulera is used for managing symptom clusters that may become intense or disruptive, helping to address core manifestations like wheezing, chest tightness, and shortness of breath. The indications for this medicine are applied in conditions involving recurrent or episodic manifestations. By working to ease these challenging symptoms, it contributes to easing the overall symptom load and helps manage the overall burden of breathing difficulties.

The medicine is considered relevant in clinical scenarios where symptoms create noticeable physiological strain, such as those that lead to night-time awakenings or limit the ability to participate in physical activity. It provides supportive relief and supports general well-being during symptomatic phases.

“The goal is to provide support that helps patients cope more steadily with symptom fluctuations in their daily routines.”

---

Quick Fact: Relief for Airway Tightness The use of this medication assists with maintaining functional stability by addressing symptoms related to inflammatory or irritative states.

Regulatory References

1. NIH DailyMed Label

Official Eligibility and Non-Eligibility Rules

Official regulatory documentation strictly defines which populations are eligible to use Dulera, focusing on age and the presence of certain medical conditions. The medicine is classified for scheduled, long-term maintenance treatment only.

Classification	Population or Condition	Constraint Details
Contraindicated (Must Not Use)	Acute Asthma/Status Asthmaticus	Prohibited for use in sudden, severe symptoms or as a rescue inhaler.
	Hypersensitivity	Contraindicated if allergic to mometasone, formoterol, or any product ingredient.
Age Restriction	Children Under 5 Years	Safety and effectiveness have not been established in patients younger than 5 years of age.
	Patients 5 Years and Older	The medicine is approved for the treatment of asthma in this age group, including adults and older adults.
Conditional Use (Use With Caution)	Cardiovascular Disorders	Caution is advised for patients with heart problems, high blood pressure, or arrhythmias.
	Metabolic/Endocrine Conditions	Caution is required for patients with diabetes mellitus or thyroid problems (thyrotoxicosis).
	Infections	Caution required in the presence of untreated or active infections (e.g., tuberculosis, fungal, viral infections) due to the corticosteroid component.
Pregnancy/Lactation	Pregnant Women	Use is conditional: only if the potential benefit justifies the potential risk to the fetus (U.S. Category C).
	Nursing Women	Caution is recommended during breastfeeding, as it is unknown if the ingredients pass into human milk.

Interaction Map: Interactions with other medicines and products — official regulatory information for Dulera

Interaction Entity Map (High-Level)	Official Interaction Patterns (Based on Regulatory Labeling)
Contraindicated Combinations	Co-administration with other Long-Acting Beta₂-Agonists (LABAs) is formally prohibited.
Pharmacokinetic Interactions	Co-administration with Strong Cytochrome P450 3A4 (CYP3A4) Inhibitors is a documented interaction leading to reduced clearance of the Mometasone component.
Exposure-Modifying Agents	Ritonavir and Cobicistat-containing products are documented to increase systemic exposure to the Mometasone component.
Pharmacodynamic Potentiation	Monoamine Oxidase Inhibitors (MAOIs), Tricyclic Antidepressants (TCAs), and QTc-prolonging drugs may potentiate cardiovascular effects.
	Xanthine Derivatives and Non-Potassium Sparing Diuretics may potentiate the risk of hypokalemia and/or ECG changes.
Pharmacodynamic Antagonism	Beta-Blockers may reduce the effectiveness of the Formoterol component, increasing the risk of severe bronchospasm.
Population-Specific Note	Caution is required for patients with hepatic impairment due to potential reduced clearance and accumulation of Mometasone.

---

Resulting Interaction Structure

The official regulatory documents define the product's interaction structure based on metabolic clearance and pharmacodynamic constraints. This structure results in a formal prohibition against co-administration with other LABAs. It further requires explicit caution with agents that inhibit Mometasone clearance, such as strong CYP3A4 inhibitors, as well as with cardiovascular-acting drugs like MAOIs, TCAs, and Beta-Blockers. The stated regulatory information delineates these restrictions and classifications without providing interpretation or clinical advice.

Ontology: Dulera Mechanism Synthesis

The way the two active components, Mometasone Furoate and Formoterol Fumarate, modulate physiological function involves two distinct molecular targets. Mometasone Furoate acts as a glucocorticoid receptor (GR) agonist, initiating a genomic mechanism where the activated GR complex translocates to the cell nucleus. There, it modulates the transcription of genes, leading to the suppression of pro-inflammatory mediators (e.g., NF-kappa B pathway) and subsequent reduction of cellular influx and tissue edema.

Formoterol Fumarate is a selective beta2-adrenergic receptor (beta2-AR) agonist that stimulates the Gs protein cascade. This increases intracellular cyclic AMP (cAMP), which inactivates the contractile apparatus in airway smooth muscle cells, resulting in a sustained relaxation state. The mechanisms exhibit synergy: beta2-AR activation enhances the nuclear migration of the GR, and Mometasone counteracts the physiological down-regulation of the beta2-AR. This combined activity supports the continuous, targeted physiological modulation of the airways.

How to Use Dulera

Dulera is an inhalation medicine prescribed for long-term maintenance treatment of airway conditions. Its usage involves a specific administration route, dosing schedule, and required technique, and it is not indicated for acute, sudden breathing episodes.

---

Official Administration Guidelines

Entity	Detail
Route of Administration	Oral inhalation only via a pressurized metered-dose inhaler (MDI).
Standard Daily Dosing	Two inhalations twice daily (morning and evening).
Adult Strengths	The standard doses are two inhalations of either the 100 mcg/5 mcg or 200 mcg/5 mcg strength twice daily.
Pediatric Strength	Patients aged 5 to < 12 years use two inhalations of the 50 mcg/5 mcg strength twice daily.
Maximum Daily Limit	Adults and adolescents must not exceed four inhalations of the 200 mcg/5 mcg strength (total 800 mcg/20 mcg).

---

Required Administration Technique

Proper use involves specific procedural steps for standardized delivery. The inhaler must be shaken well and primed with four test sprays before first use or if unused for more than five days. When administering the dose, a 30-second interval must be observed between the first and second actuation. Crucially, after each dose (two puffs), patients are required to rinse the mouth with water and spit immediately, ensuring the water is not swallowed. If a dose is missed, it should not be made up by taking extra actuations; the next dose should be taken at the scheduled time.

Research Evidence / Overview of Studies for Dulera

Evidence from Clinical Trials for Persistent Asthma

The body of research for the Mometasone/Formoterol fixed-dose combination centers on Randomized Controlled Trials (RCTs). These are controlled studies that compare the medicine against its individual components (Mometasone alone or Formoterol alone), or a placebo. This structure was applied in research contexts involving fluctuating or unstable symptoms to examine how the medicine was evaluated for its evaluation as a long-term, scheduled maintenance option for persistent asthma. Trials typically lasted 12 to 26 weeks. Studies focused on Adults and Adolescents (≥ 12 years) whose enrollment criteria specified persistent asthma symptoms not fully controlled by a preceding inhaled corticosteroid therapy.

The evidence derived from settings with varying symptom burdens helps to provide context on how the medicine was studied for regulatory review.

---

Assessment of Pulmonary Function and Disease Stability

This section details the two main categories of outcomes related to systemic or functional imbalance that were monitored in the trials. The primary outcomes studied were changes in objective measurements of lung function, such as the forced expiratory volume in 1 second ( FEV1). Studies reported patterns of change in pulmonary function ( FEV1 values) from baseline when the fixed-dose combination was observed in study participants, compared to those taking Mometasone alone or a placebo.

In addition to function, studies monitored measures of disease stability, such as the timing and frequency of asthma exacerbation events. These are outcomes describing episodic or acute changes that can lead to emergency treatment or the need for oral steroids. Trials reported that the fixed combination was associated with differences in the rate of these events compared to cohorts receiving Formoterol alone, contributing to the evidence base related to a fixed-dose combination approach.

---

Evidence in Specific Patient Groups and Uncertainties

The initial evidence primarily focused on adults and adolescents. However, the medicine was evaluated in a specific Pediatric population of children aged 5 to 11 years with persistent asthma. Studies describe patterns of measured change in the children's lung function in the group receiving the fixed-dose combination.

For long-term evaluation, large-scale safety trials were required to observe outcomes monitoring physiological strain or stress and serious asthma-related events over extended time intervals, often up to 52 weeks (one year). These studies add to the research landscape by providing data on the observations and patterns reported over extended treatment intervals. The results apply only to the populations studied and the specific conditions under which the research was conducted, and long-term effects are not fully established beyond the one-year study mark.

Key Studies & References A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (SPIRO) (NCT01471340)

Common questions about Dulera (FAQ)

Q: What happens if I stop using Dulera suddenly?

Regulatory documents indicate that Dulera is a maintenance medication and is not intended to be stopped suddenly. The labeling advises that changing the dose or stopping treatment without consulting a healthcare provider may be associated with a loss of asthma control or worsening of breathing problems.

Q: How do I know if the Dulera inhaler is empty?

The Dulera inhaler includes a dose counter on the top of the canister that displays the number of remaining inhalations. The official instructions indicate that the inhaler should be disposed of once the counter displays zero doses remaining.

Q: What should the expiration date look like on a Dulera inhaler?

The expiration date is printed on both the canister and the outer carton. Product information advises against using the medicine after this date. Expired inhalers should be disposed of according to recommended guidelines.

Q: Is Dulera used for conditions other than asthma and COPD?

According to official regulatory labeling, Dulera is approved for the long-term maintenance treatment of asthma in patients aged 5 years and older. Its approved use is limited to this condition.

Q: Are there studies on the long-term effects of using Dulera?

Clinical trials used for regulatory review typically study the combination medicine over periods up to 52 weeks (one year). Official prescribing information indicates that longer-term effects beyond the clinical study period of approximately one year are not fully established.

Q: What is the onset of action for the formoterol component of Dulera?

Formoterol, one of the two active components, is a fast-acting bronchodilator component. Official pharmacological data indicates that its initial effect on opening the airways may be observed within minutes after inhalation.

Q: Can I use my Dulera inhaler if it has been exposed to extreme heat or cold?

Regulatory information indicates the pressurized canister should be stored at controlled room temperature and protected from heat. Official warnings state that exposure to temperatures above 120 F (49 C) may cause the canister to burst, which could affect the medicine.

Q: Can using Dulera make me more susceptible to infections?

The mometasone component is an inhaled corticosteroid, and its use may be associated with an increased risk of infection, such as a localized yeast infection (thrush) in the mouth and throat. Official warnings note that the medication may also worsen existing infections, such as tuberculosis.

Q: Is Dulera a Daily medication?

Yes, Dulera is a controller medication intended for scheduled, daily administration. Official dosing instructions indicate it is generally taken twice daily, every day, for continuous long-term management.

Q: Are there specific instructions for cleaning the Dulera inhaler?

Instructions for use are provided for cleaning the plastic actuator (the mouthpiece) to prevent medicine buildup. The directions also specify that the canister itself should not be exposed to water or moisture.

Q: How should I dispose of an empty or expired Dulera inhaler?

The inhaler should be disposed of once the dose counter reaches zero. Because the canister is pressurized, it must not be put into an open fire or incinerator. Local guidelines should be followed for safe disposal of the expired or empty inhaler.

Q: Can Dulera affect my eyes or cause blurred vision?

The inhaled corticosteroid component has been linked to potential eye issues with long-term use. Official documents mention that effects like cataracts, glaucoma, and blurred vision have been reported. Eye health monitoring may be recommended by a healthcare provider.

Q: Is it common to feel shaky or have a fast heart rate after taking Dulera?

The formoterol component is a beta2-agonist, which can cause symptoms like tremor (shakiness) or a fast or irregular heartbeat (tachycardia). These are listed in the official documents as potential side effects, especially if the dose is higher than recommended.

Q: Is it true that Dulera can increase the risk of pneumonia?

For patients with underlying chronic lung conditions, the inhaled corticosteroid component found in Dulera has been associated with an increased risk of developing pneumonia. Official warnings draw attention to this potential risk.

Q: Does Dulera contain lactose or other common allergens?

Official prescribing information lists all active and inactive ingredients. The medicine is formally contraindicated if a person has a known allergy or hypersensitivity to the active ingredients (mometasone, formoterol) or any other component in the product.

Storage and Disposal Requirements for Dulera

Dulera (mometasone furoate and formoterol fumarate dihydrate) must be stored at controlled room temperature, defined as 68 F to 77 F (20 C to 25 C). The pressurized canister must be protected from extreme heat, open flame, and puncture, as temperatures exceeding 120 F (49 C) can cause it to burst.

Canister and Handling Rules

Item	Requirement
Positional Rule (60-Actuation)	Must be stored with the mouthpiece down or sideways after priming.
Container Integrity	Do not remove the canister from the actuator.
Child Safety	Keep Dulera and all medicines out of the reach of children.

Disposal Instructions

Regulatory labeling requires the inhaler to be discarded when the dose counter reaches zero. The pressurized container must not be thrown into a fire or incinerator. Unused medicine should be disposed of safely after consulting a healthcare professional or pharmacist.